A Phase II Randomized Double-Masked Trial of Pegaptanib, an Anti–Vascular Endothelial Growth Factor Aptamer, for Diabetic Macular Edema
Top Cited Papers
- 31 October 2005
- journal article
- clinical trial
- Published by Elsevier BV in Ophthalmology
- Vol. 112 (10), 1747-1757
- https://doi.org/10.1016/j.ophtha.2005.06.007
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Pegaptanib for Neovascular Age-Related Macular DegenerationThe New England Journal of Medicine, 2004
- Intrachoroidal Neovascularization in Transgenic Mice Overexpressing Vascular Endothelial Growth Factor in the Retinal Pigment EpitheliumThe American Journal of Pathology, 2001
- UKPDS 50: Risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosisDiabetologia, 2001
- Vascular Endothelial Growth Factor Is Sufficient to Produce Iris Neovascularization and Neovascular Glaucoma in a Nonhuman PrimateAmerican Journal of Ophthalmology, 1996
- Inhibition of Vascular Endothelial Growth Factor Prevents Retinal Ischemia—Associated Iris Neovascularization in a Nonhuman PrimateAmerican Journal of Ophthalmology, 1996
- Vascular Endothelial Growth Factor in Ocular Fluid of Patients with Diabetic Retinopathy and Other Retinal DisordersThe New England Journal of Medicine, 1994
- Detection of Vascular Endothelial Growth Factor Messenger RNA and Vascular Endothelial Growth Factor-like Activity in Proliferative Diabetic RetinopathyAmerican Journal of Ophthalmology, 1994
- The Effect of Intensive Treatment of Diabetes on the Development and Progression of Long-Term Complications in Insulin-Dependent Diabetes MellitusThe New England Journal of Medicine, 1993
- Vascular Endothelial Growth Factor Is a Secreted Angiogenic MitogenScience, 1989
- Tumor Angiogenesis: Therapeutic ImplicationsThe New England Journal of Medicine, 1971